RT Journal Article
SR Electronic
T1 Clinical performance of cell free DNA for fetal RhD detection in RhD-negative pregnant individuals in the US
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.24.24310793
DO 10.1101/2024.07.24.24310793
A1 Mateus Nino, Julio F.
A1 Wynn, Julia
A1 Wiggins-Smith, Jenny
A1 Bryant, J. Brett
A1 Citty, J. Kris
A1 Citty, J. Kyle
A1 Ahuja, Samir
A1 Newman, Roger
YR 2024
UL http://medrxiv.org/content/early/2024/12/07/2024.07.24.24310793.abstract
AB Objective We aimed to evaluate the performance of a cell free DNA (cfDNA) assay that uses next generation sequencing (NGS) with quantitative counting templates (QCT) for the clinical detection of the fetal RHD genotype in a diverse RhD-negative pregnant population in the United States (US).Study Design This retrospective cohort study was conducted in four US healthcare centers. The same NGS QCT cfDNA fetal RhD assay was offered to non-alloimmunized, RhD-negative pregnant individuals as part of clinical care. Rh immune globulin (RhIG) was administered at the discretion of the provider. The assay’s sensitivity, specificity, and accuracy were calculated considering the neonatal RhD serology results.Results A total of 401 non-alloimunized RhD-negative pregnancies who received clinical care in the period from August 2020 to November 2023 were included in the analysis. The D antigen cfDNA result was 100% concordant with the neonatal serology, resulting in 100% sensitivity, 100% positive predictive value (both 95% CI: 98.6%-100%), 100% specificity, and 100% negative predictive value (both 95% CI: 97.4%-100%). There were 10 pregnancies where the cfDNA analysis identified a non-RHD gene deletion, including RhDΨ (n=5) and RHD-CE-D hybrid variants (n=5). RhIG was administered to 93% of pregnant individuals with cfDNA results indicating an RhD-positive fetus compared to 75% of pregnant individuals with cfDNA results indicating an RhD-negative fetus, signifying providers were using the results to guide pregnancy management.Conclusion This cfDNA analysis via NGS for detecting fetal RhD status is highly accurate with no false-positive or false-negative results in 401 racially and ethnically diverse pregnancies with 100% follow up of all live births. This study and prior studies of this assay support a recommendation to offer cfDNA screening for fetal Rh status as an alternative option to prophylactic RhIG for all non-alloimmunized RhD-negative individuals, which will result in more efficient and targeted prenatal care with administration of RhIG only when medically indicated.Competing Interest StatementDr. Samir Ahuja is a paid consultant from BillionToOne, Inc. Julia Wynn is an employee of BillionToOne, Inc. and has stock options in the company. Drs. Jenny Wiggins-Smith, J. Bret Bryant, J. Kris Citty, J. Kyle Citty and Samir Ahuja received funding for this research project from BillionToOne, Inc.Funding StatementParticipating clinical sites received research funding from the sponsor of the study, BillionToOne Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participating institutions and the sponsor site received approved by the WCG IRB (IRB#: 20234135). The study was exempted from patient consent as it was a retrospective study of medical records from clinical care.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesA complete set of anonymized data is available on request from the corresponding author.